January 7, 2026 | San Antonio, TX & Firle, South Australia – Avance Clinical, a global contract research organization focused on accelerating clinical development for biotech sponsors, today announced the acquisition of LumaBridge, a specialized U.S.-based clinical CRO with deep expertise in oncology trials. This strategic acquisition expands Avance’s existing U.S. presence and marks a significant milestone in accelerating the company’s growth in oncology, the largest and fastest-growing therapeutic area in global R&D. Both organizations share a commitment to deliver high quality, innovative and efficient oncology clinical trials that accelerate the development of next-generation therapies to patients worldwide.
